

A1 cont
transcripts, A (SEQ ID NO:2) and B (SEQ ID NO:4). The A transcript is SP22A and is unique to the testis and referred to as SEQ ID NO:2.--

Please replace the paragraph numbered 39 of page 13 with the following rewritten paragraph:

A2
--[0039.] Figure 8 is a plot illustrating the immunoreactivity of overlapping 15 mer SP22 peptides with affinity-purified anti-SP22 peptide Ig. Antiserum was affinity-purified and diluted 1:100 prior to use. The two reactive peaks within the 189 amino acid SP22 sequence are: Peptide A (TVAGLAGKDPVQCSR) (residues 34-48 of SEQ ID NO:3) and Peptide B (DGLILTSR) (residues 149-156 of SEQ ID NO:3).--

Please replace the paragraph numbered 44 of page 15 with the following rewritten paragraph:

A3
--[0044.] Figure 13 is a plot illustrating the immunoreactivity of overlapping 15 mer PS-22 peptides with affinity-purified anti-recombinant SP22 Ig. Antiserum was affinity-purified and diluted 1:100 prior to use. The three reactive peaks within the 189 amino acid SP22 sequence are: Peptide C (LEEAKTQGPYDV) (residues 58-69 of SEQ ID NO:3), Peptide D (VKEILKEQENRKGLI) (residues 88-102 of SEQ ID NO:3), and Peptide E (GFGCKVTSHPLAKDK) (residues 118-132 of SEQ ID NO:3).--

Please replace the paragraphs numbered 46 and 47 of page 16 with the following rewritten paragraphs:

4
A
--[0046.] Figure 15 shows the nucleotide (bases 192-980 of SEQ ID NO:2) and amino acid (SEQ ID NO:3) sequences of SP22.

[0047.] Figure 16 shows the longer 5' untranslated regions of SP22A (bases 1-975 of SEQ ID NO:2 and SEQ ID NO:3).--

IN THE DRAWINGS

A.E.
Attached hereto are copies of Figures 2, 8 and 13 with proposed revisions marked. The proposed revisions to Figure 2 are marked in red. The proposed revisions to Figures 8 and 13 have been typed in (identifications of SEQ ID NO:3 residues) and marked in red. Approval of these revisions is respectfully requested.

IN THE SEQUENCE LISTING

Please enter the attached Sequence Listing, numbered as pages 1-4.